IL-37 Expression Is Downregulated in Lesional Psoriasis Skin

Immunohorizons. 2020 Nov 25;4(11):754-761. doi: 10.4049/immunohorizons.2000083.

Abstract

IL-37 broadly suppresses inflammation in various disease models. However, studies of the regulation and role of IL-37 in psoriasis are limited and contradictive. Using transcriptome analysis, PCR, protein determination, and immunofluorescence, we demonstrated marked downregulation of IL-37 in biopsies from human lesional psoriasis skin compared with paired samples of nonlesional skin. Immunofluorescence analysis showed that IL-37 was localized to stratum granulosum of the epidermis. TNF-α stimulation of normal human epidermal keratinocytes led to increased IL37 expression through a p38 MAPK-mediated mechanism, whereas IL-17A, IL-17C, IL-17F, and IL-22 acted suppressively. Intradermal injection with recombinant human IL-37 into imiquimod-induced psoriasis skin of C57BL/6J mice demonstrated a trend toward a protective effect, however NS. Altogether, these results demonstrate that IL-37 is downregulated in human lesional psoriasis skin. This may be a consequence of the loss of stratum granulosum, but key cytokines in the development of psoriasis also seem to contribute to this downregulation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Disease Models, Animal
  • Down-Regulation
  • Female
  • Humans
  • Imiquimod
  • Inflammation / metabolism
  • Interleukin-1 / genetics
  • Interleukin-1 / metabolism*
  • Interleukin-17 / metabolism*
  • Keratinocytes / pathology*
  • Mice
  • Mice, Inbred C57BL
  • Psoriasis / metabolism
  • Psoriasis / pathology*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • IL37 protein, human
  • Interleukin-1
  • Interleukin-17
  • Tumor Necrosis Factor-alpha
  • Imiquimod